0001209191-22-062627.txt : 20221223 0001209191-22-062627.hdr.sgml : 20221223 20221223164730 ACCESSION NUMBER: 0001209191-22-062627 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20221221 FILED AS OF DATE: 20221223 DATE AS OF CHANGE: 20221223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RENSCHLER MARKUS MD CENTRAL INDEX KEY: 0001217598 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40499 FILM NUMBER: 221485899 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS INC STREET 2: 995 E ARQUES AVE CITY: SUNNYVALE STATE: CA ZIP: 94085-4521 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc. CENTRAL INDEX KEY: 0001662244 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455429901 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-285-4140 MAIL ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-21 0 0001662244 Cyteir Therapeutics, Inc. CYT 0001217598 RENSCHLER MARKUS MD C/O CYTEIR THERAPEUTICS, INC. 128 SPRING ST, BUILDING A, SUITE 510 LEXINGTON MA 02421 1 1 0 0 President and CEO Common Stock 2022-12-21 4 M 0 106345 1.03 A 948299 D Common Stock 2022-12-21 4 M 0 30437 1.20 A 978736 D Stock Option (Right to Buy) 1.03 2022-12-21 4 M 0 106345 0.00 D 2028-12-10 Common Stock 106345 0 D Stock Option (Right to Buy) 1.20 2022-12-21 4 M 0 30437 0.00 D 2030-02-24 Common Stock 30437 32973 D Due to rounding in connection with the Issuer's reverse stock split during its initial public offering, the exercise price and the number of securities underlying this option were immaterially incorrect as reported on the Reporting Person's Form 3 filing on June 17, 2021. These numbers have been corrected in this Form 4. The option vested at a rate of 18,334 shares per month at the end of each successive one-month period beginning January 3, 2019, for 40 months, and at a rate of 14,703 shares per month at the end of the 41st month, at which point the option was fully vested. The option vests as to 1/48th of the underlying shares of common stock on February 1, 2020, and at the same rate at the end of each successive one-month period following such date until the fourth anniversary of such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Exhibit List: Exhibit 24 - Power of Attorney /s/ Adam M. Veness, as attorney-in-fact for Markus Renschler, M.D. 2022-12-23 EX-24 2 poa.txt POA DOCUMENT SUBSTITUTE POWER OF ATTORNEY Pursuant to the Limited Power of Attorney of Markus Renschler (the "Power of Attorney"), dated May 21, 2021 and filed with the Securities and Exchange Commission, the undersigned has been constituted and appointed true and lawful attorney-in-fact, with full power of substitution, to, on behalf of Dr. Renschler: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC; (2) execute for and on behalf of the undersigned, in the undersigned's capacity as officer and/or director of Cyteir Therapeutics, Inc. (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and (4) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by each such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as each such attorney-in-fact may approve in each such attorney-in-fact's discretion. Pursuant to the powers granted to the undersigned in the Power of Attorney, the undersigned hereby constitutes and appoints Adam Veness as a substitute to the undersigned attorney-in-fact, with full power of substitution, and with full power and authority to do and perform every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of the rights and powers granted to the undersigned in said Power of Attorney. For the avoidance of doubt, the foregoing appointment shall not serve as a revocation of the powers granted to the undersigned himself in the Power of Attorney. This Substitute Power of Attorney shall remain in full force and effect unless and until revoked by the undersigned. [Remainder of page intentionally left blank] IN WITNESS WHEREOF, the undersigned has caused this Substitute Power of Attorney to be executed as of this 23rd day of December, 2022. /s/ David Gaiero ------------------- David Gaiero